Evaluation of the New Variant 501Y.V2 of COVID-19

Centre Hospitalier Régional Metz-Thionville250 enrolled

Overview

In January 2021, the incidence of COVID-19-and its mortality started rising for the third time in France. This rise may associate with three emerging variants, namely, V1, V2, and V3, which are the 20I/501Y.V1 ("English"), 20H/501Y.V2 ("South African"), and 20J/501Y.V3 ("Brazilian") variants, respectively. V1 was recently suggested to increase mortality in people in the United Kingdom who tested positive for COVID-19 on community screening. Very little is known about V2 infection, including its outcomes relative to other strains. In early 2021, V2 spread to the Grand-Est region (northeastern France). Here, the investigators aimed to report mortality data of patients admitted in ICU between February and April 2021 in 3 hospitals in Grand-Est: Metz, Thionville and Nancy.

Study Type

OBSERVATIONAL

Enrollment

250

Conditions

Covid19

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Admission in ICU in February, March or April 2021 * Patient with a SARS-CoV-2 positive polymerase-chain reaction test * Patient with 20I/501Y.V1 ("English") or 20H/501Y.V2 ("South African") SARS-CoV-2 variants Exclusion Criteria: * Opposed to use data

Locations (2)

CHRU Nancy

Nancy, Meurthe-et-moselle, France

Outcomes

Primary Outcomes

Mortality 28 days after admission

Vital status 28 days after admission in Intensive Care Unit

Time frame: Day 28

Secondary Outcomes

ICU mortality

Percentage of mortality in Intensive Care Unit

Time frame: Day 1